JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Akcijų sąrašas・Champions Oncology Inc

Search

C
Champions Oncology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

5.89 3.33

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.8100000000000005

Max

6

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-514K -278K
Pardavimai	1.5M 17M
P/E Sektoriaus vid.	35.118 67.147
Pelnas, tenkantis vienai akcijai	-0.02
Pelno marža	-1.679
Darbuotojai	213
EBITDA	-458K 154K

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-22

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	697K 84M
Ankstesnė atidarymo kaina	2.56
Ankstesnė uždarymo kaina	5.89

Naujienos nuotaikos

By Acuity

50%

50%

176 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

5.77 / 7.61 Palaikymas ir pasipriešinimas

Champions Oncology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-04 22:17; UTC

Uždarbis

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

2026-05-04 23:47; UTC

Uždarbis

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

2026-05-04 23:45; UTC

Uždarbis

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

2026-05-04 23:45; UTC

Uždarbis

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

2026-05-04 23:40; UTC

Rinkos pokalbiai

Gold Steady Amid Likely Technical Recovery -- Market Talk

2026-05-04 22:44; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Jim Beyer To Be Chief Executive of Combined Company

2026-05-04 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

2026-05-04 22:42; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

2026-05-04 22:42; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

2026-05-04 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

2026-05-04 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Pro Forma Market Capitalization About A$10.7 Billion

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Shareholders to Own About 51% of Combined Company

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Board Unanimously Endorsed, Supported Deal

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Deal Unanimously Recommended by Vault Board

2026-05-04 22:39; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

2026-05-04 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Regis Resources to Acquire All Ordinary Shares in Vault

2026-05-04 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Regis Resources, Vault Minerals Agree to Merger of Equals

2026-05-04 22:37; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

2026-05-04 22:26; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

2026-05-04 22:02; UTC

Uždarbis

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

2026-05-04 22:00; UTC

Rinkos pokalbiai

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

2026-05-04 21:52; UTC

Uždarbis

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

2026-05-04 21:50; UTC

Uždarbis

Westpac: Some Sectors More Affected Than Others>WBC.AU

2026-05-04 21:50; UTC

Uždarbis

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

2026-05-04 21:49; UTC

Uždarbis

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

2026-05-04 21:44; UTC

Uždarbis

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

2026-05-04 21:44; UTC

Uždarbis

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

2026-05-04 21:43; UTC

Uždarbis

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

2026-05-04 21:41; UTC

Uždarbis

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

2026-05-04 21:40; UTC

Uždarbis

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Akcijų palyginimas

Kainos pokytis

Champions Oncology Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

0

Pirkti

0

Laikyti

0

Parduoti

Remiantis 0 analitikų, pateikusių Champions Oncology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

5.77 / 7.61Palaikymas ir pasipriešinimas

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

176 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Kitos sektoriaus akcijos

JNJ

Johnson and Johnson

225.57

UNH

UnitedHealth Group Inc

363.82

TMO

Thermo Fisher Scientific Inc

466.62

ISRG

Intuitive Surgical Inc

451.55

ABT

Abbott Laboratories

87.15

Live chat